目的 分析四川大学华西医院麻醉性镇痛药应用的现状及趋势，并行客观评价。 方法 对2008年－2010年四川大学华西医院麻醉性镇痛药品的种类、用量、金额、用药频度等进行归类统计、比较和分析。 结果 住院部使用麻醉药品的用量及金额呈上升趋势。临床应用以芬太尼类居首。新型麻醉药品的应用也有上升趋势。 结论 麻醉性镇痛药的应用基本合理，但创建无痛医院仍需进一步完善，并提交合理用药水平。
目的 研究环氧合酶-2抑制剂药物的应用状况和发展趋势，为临床合理、有效、经济地选用药物提供科学依据。 方法 采用金额排序和用药频度（DDDs）、日均费用（DDC）方法，对四川大学华西医院2008年－2010年环氧合酶-2抑制剂药物的临床应用情况进行统计分析。 结果 2008年－2010年间，该院环氧合酶-2抑制剂药物的应用数量和销售金额呈逐年上升趋势，其中选择性环氧合酶-2抑制剂药物的用量增幅较大，非选择性环氧合酶-2抑制剂药物用量呈下降趋势。 结论 该院环氧合酶-2抑制剂药物临床应用合理，选择性环氧合酶-2占主导地位，有较好的发展前景。
【摘要】 目的 评价临床心血管系统药物的利用情况与趋势。 方法 利用excel表格对四川省建筑医院2008年1月－2010年12月全部心血管系统药物处方的种类、销售金额、用药频度值（DDDs）等进行统计分析。 结果 3年中，心血管系统药物的销售金额呈逐年上升趋势。在销售金额和DDDs的前10名排名中主要包括钙通道阻滞类药物、调血脂药物和中成药等。 结论 临床心血管系统药物应用基本合理，对于疗效显著、不良反应轻微、价格合理的药物患者依从性好，临床使用广泛。【Abstract】 Objective To investigate the use of cardiovascular drugs in our hospital (Sichuan Architecture Hospital) from 2008 to 2010, and evaluate its future tendency. Methods Excel was used to analyze the variety, consumption, defined daily dose (DDDs) of cardiovascular drugs used during 2008 to 2010 statistically in our hospital. Results During these three years, the consumption of cardiovascular drugs increased from year to year. The calcium channel blockers, lipid-modulating drugs and traditional Chinese medicines ranked high in the sum and DDDs column in Excel. Conclusion The use of cardiovascular drugs is rational in our hospital. The safe and effective drugs with reasonable price and better compliance are widely applied.
目的 了解2007年-2008年成都地区17家医院消化系统药物的使用状况。 方法 采用限定日剂量（DDD）的方法，对成都地区2007年-2008年17家医院消化系统用药的销售金额、用药频度（DDDs）等进行统计分析。 结果 2007-2008年成都地区17家医院消化系统用药总金额分别为12 527.89万元和16 446.21万元，居所有药物销售总额的第5位。在金额排序和用药频度排序中，抗溃疡药、肝病用药居于前列。 结论 消化系统药物的应用状态与同期的整体增长保持一致，相比上一年略有上涨。抗溃疡药中的质子泵抑制剂以其优异的性价比，引领着消化系统药物销售额的增长。
【摘要】 目的 了解2007年-2008年成都地区17家医院抗肿瘤药物的使用情况。 方法 以销售金额、用药频度（DDDs）对2007年、2008年成都地区17家医院抗肿瘤药物消耗数据进行分类统计、综合分析、对比。 结果 2008年成都地区17家医院抗肿瘤药物用药金额增长幅度较大，各亚类抗肿瘤药物中其它类抗肿瘤药物类、植物来源的抗肿瘤药、抗代谢药金额排序依次占前3位。销售金额前100位药物中，肿瘤药物占据8位，大多数是其它类抗肿瘤药物，且其用药频度也靠前。 结论 抗肿瘤药物用药金额和用药量都将快速增长，其中其它类抗肿瘤药物和植物来源的抗肿瘤药的发展尤被看好。【Abstract】 Objective To evaluate the situation of antineoplastics used in Chengdu area from 2007 to 2008. Methods The consumption data of antineoplastics used in 17 hospitals of Chengdu area in 2007 and 2008 were classified, and the consumption sum and defined daily doses (DDDs) were analyzed. Results The total consumption sum of antineoplastics in 2008 increased sharply. Other antineoplastics, herbal-sourced antineoplastics and antimetabolism drugs ranked in the first three places. Among the top drugs in terms of consumption sum, antineoplastics took 8 places. Conclusion The consumption sum and DDDs of antineoplastics, especially other antineoplastics and herbal-sourced antineoplastics, will increase rapidly.
目的：了解2007年成都地区17家医院间心血管系统药物的使用状况。方法：采用限定日剂量(DDD)的方法，对成都地区2007年17家医院中心血管系统用药的销售金额、用药频度(DDDs)等进行统计分析。结果：2007年成都地区17家医院心血管系统用药总金额为13 753.86万元，占所有药物销售总额的9.05%。在金额排序和用药频度排序前列中，主要包括中药制剂、钙离子拮抗剂等，中药制剂类产品也销售状况良好。结论：中药制剂发挥巨大作用，依从性好、不良反应发生率低、疗效确切的药物已成为临床医师治疗心血管疾病的首选。
摘要:目的:了解2007~2008年成都地区17家医院生物制品及生化药品的使用状况。方法:采用限定日剂量(DDD)的方法,对成都地区2007~2008年17家医院生物制品及生化药品的销售金额、用药频度(DDDs)等进行统计分析。结果:2007年、2008年成都地区17家医院生物制品及生化药品销售总额分别为7338万元、9786万元;分别占总销售额的4.83%、5.00%。销售金额进入总销售额排名前100位的生物制品及生化药品有:人血白蛋白、胸腺肽、丙种球蛋白、促白细胞生长素和环磷腺苷。环磷腺苷在生物制品及生化药品中的DDDs最高。结论:生物制品及生化药品的价格及供给对其临床使用有较大的限制。Abstract: Objective: To evaluate the current situation and the trend of biological products and biochemical drugs used in Chengdu city in 2007 to 2008. Methods: Consumption of biological products and biochemical drugs used in 17 hospitals of Chengdu city in 2007 to 2008 were analyzed by the way of sum DDD and DDDs ranking. Results: The total cost of the biological products and biochemical drugs used in Chengdu city in was 73.38 and 97.86 million yuan in 2007 to 2008, it accounted for 4.83% and 5.00% of the total cost. Human serum albumin, thymosin, gamma globulin, interleukin promoting growth hormone and adenosine cyclophosphate were the drugs in the first 100 cost list. The DDDs of adenosine cyclophosphate was highest among biological products and biochemical drugs. Conclusion: The cost and supply of biological products and biochemical drugs were great limitations of their clinical application.
Objective To investigate the utilization of platinum drugs in 21 hospitals of Chengdu from 2011 to 2014. Methods The utilization information of platinum drugs in 21 hospitals of Chengdu from 2011 to 2014 was extracted, and the dosage form of drugs, consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results From 2011 to 2014, the total consumption sums and DDDs of platinum drugs were increased year by year. The consumption sums of oxaliplatin were the highest, and the consumption sums of carboplatin were increased year by year. Oxaliplatin, nedaplatin, and lobaplatin were ranked first, second and fifth respectively in all the four consecutive years; the total DDDs of patinum drugs from 2011 to 2014 showed a trend of increase, DDDs of cisplatin were always ranked first, followed by oxaliplatin; DDC and sorting of platinum drugs were relatively stable, and B/A values of carboplatin and cisplatin were close to 1.00. Conclusion The utilization of platinum drugs in 21 hospitals of Chengdu is in accordance with the principle of safety, effectiveness, economy and convenience.